Prognosis of aortic valve sclerosis in cardiovascular mortality of patients seen at the Cardiology Institute of Rio Grande do Sul;Prognóstico da esclerose valvar aórtica na mortalidade cardíaca de pacientes atendidos no Instituto de Cardiologia do Rio Grande do Sul

Arquivos Brasileiros de Cardiologia

Volumn 88, Issue 2, 2007, Pages

  Da Rosa, Eduardo Maffini ^a,b   Sant'anna, João Ricardo Michielin ^a   Oppermann, Luciana Pimentel ^a   Castro, Iran ^a,b  

^a INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^b Fundação Universitária de Cardiologia ^*  (Brazil)

Author keywords

Echocardiography; Heart valve diseases prevention mortality

Indexed keywords

ADULT; AGED; AORTA VALVE DISEASE; AORTIC VALVE SCLEROSIS; ARTICLE; BRAZIL; CARDIOMYOPATHY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY CARE UNIT; DATA BASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DEATH; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; REGISTER; AORTA VALVE; CARDIOVASCULAR DISEASE; ECHOGRAPHY; EPIDEMIOLOGY; MIDDLE AGED; PATHOLOGY; SCLEROSIS;

AGED; AORTIC VALVE; CARDIOVASCULAR DISEASES; ECHOCARDIOGRAPHY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SCLEROSIS;

EID: 33947596896     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2007000200016     Document Type: Article

References (49)

1. Otto CM. Why aortic sclerosis is associated with adverses clinicas outcomes? J Am Coll Cardiol. 2004; 43: 176-8.
2. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of degenerative valvular aortic stenosis: histological and immunohistochemical studies. Circulation. 1994; 90: 844-53.
3. Gerber Y, Goldbourt U, Fleinberg MS, Segev S, Harats D. Are triglyceriderich lipoproteins associated with aortic valve sclerosis: a preliminary report. Atherosclerosis. 2003; 170: 301-5.
4. Chang KL. Is aortic stenosis a preventable disease? J Am Coll Cardiol. 2003; 42: 593-9.
5. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arterioscler Thromb Vasc Biol. 1996; 16: 523-32.
6. Gotoh T, Kuroda T. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol. 1995; 76: 928-32.
7. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997; 29: 630-4.
8. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aorticvalve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999; 341:142-7.
9. Mohler ER III, Adam LP, McClelland P, Graham L, Hathaway DR. Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol. 1997; 17: 547-52.
10. Jian B, Jones PL, Li Q, Mohler ER III, Schoen FJ, Levy RJ. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol. 2001; 159: 321-7.
11. Shavelle DM, Takasu J, Budoff MJ, Mao S, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002; 359:1125-6.
12. O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2002; 106: 2224-30.
13. Mohler ER III, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis. 1999; 8: 254-60.
14. Poggianti E, Venneri L, Chubuchny V, Jambrik Z, Baroncini LA, Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol. 2003; 41:136-41.
15. Chandra HR, Goltstein JA, Choudbary N. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol. 2004; 43: 169-75.
16. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001; 88: 693-5.
17. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001; 104: 2205-9.
18. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Heart outcomes prevention evaluation study investigators: effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-53.
19. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995-1003.
20. Fox KM, Bertrand M, Ferrari R et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease. Lancet. 2003; 362: 782-8.
21. O'Brien KD, Kuusisto J, Reichenbach DD, Ferguson M, Giachelli C, Alpers CE, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation. 1995; 92: 2163-8.
22. Carabello BA. Aortic sclerosis: a window to the coronary arteries? New Eng J Med. 1999; 341:193-5.
23. Getchell WS. Aortic: valve sclerosis. N Eng J Med. 1999; 341:1856-7.
24. Honda T, Yano K, Matsuoka H, Hamada M, Hiwada K. Evaluation of aortic distensibility in patients with essential hypertension by using cine magnetic resonance imaging. Angiology. 1994; 45: 202-12.
25. Taylor HA Jr, Clark BL, Garrison RJ, Andrew ME, Han H, Fox ER, et al. Relation of aortic valve sclerosis to risk of coronary heart disease in African-Americans. Am J Cardiol. 2005; 95: 401-4.
26. Hsu SY, Hsieh IC, Chang SH, Wen MS, Hung KC. Aortic valve sclerosis is an echocardiographic indicator of significant coronary disease in patients undergoing diagnostic coronary angiography. Int J Clin Pract. 2005; 59: 72-7.
27. Agno FS, Chinali M, Bella JN, Liu JE, Arnett DK, Kitzman DW, et al. Aortic valve sclerosis is associated with preclinical cardiovascular disease in hypertensive adults: the Hypertension Genetic Epidemiology Network study. J Hypertens. 2005; 23: 867-73.
28. Rajani R, Chambers J. Aortic valve 'sclerosis': a clinically useful marker in coronary disease? Int J Clin Pract. 2005; 59: 381-3.
29. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836-43.
30. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998; 97: 2007-11.
31. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000; 343: 1139-47.
32. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997; 96: 778-84.
33. Chandra HR, Choudhary N, O'Neill C, Boura J, Timmis GC, O'Neill WW. Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS). Am J Cardiol. 2001; 88: 214-8.
34. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657-71.
35. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 2165-8.
36. Prasad Y, Bhalodkar NC. Aortic sclerosis: a marker of coronary atherosclerosis. Clin Cardiol. 2004; 27: 671-3.
37. Poggianti E, Venneri L, Chubuchny V, Jambrik Z, Baroncini LA, Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol. 2003; 41: 136-41.
38. Chan KL. Is aortic stenosis a preventable disease? J Am Coll Cardiol. 2003; 42: 593-9.
39. Olsen MH, Wachtell K, Bella JN, Liu JE, Boman K, Gerdts E, et al. Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol. 2004; 94: 1076-80.
40. Olsen MH, Wachtell K, Wachtell K, Gerdts E. Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). Am J Cardiol. 2005; 95:132-6.
41. Aronow WS, Ahn C, Shirani J, Kronzon I. Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis. Am J Cardiol. 1999; 83: 599-600.
42. Stewart BF, Siscovick D, Lind BK, Gardim JM, Gottdienor JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997; 29: 630-4.
43. Suzuki S, Sato K, Taniguchi M, Miyagawa K, Kojima M, Dohi Y, et al. Clinical significance of serum lipoprotein(a) in elderly patients with aortic valve sclerosis. Nippon Ronen Igakkai Zasshi. 1998; 35: 444-50.
44. Hsu SY, Hsieh IC, Chang SH, Wen MS, Hung KC. Aortic valve sclerosis is an echocardiographic indicator of significant coronary disease in patients undergoing diagnostic coronary angiography. Int J Clin Pract. 2005; 59: 72-7.
45. Rossi A, Bertagnolli G, Cicoira M, Golia G, Zanolla L, Santini F, et al. Association of aortic valve sclerosis and coronary artery disease in patients with severe nonischemic mitral regurgitation. Clin Cardiol. 2003; 26: 579-82.
46. Jeon DS, Atar S, Brasch AV, Luo H, Mirocha J, Nagvi TZ, et al. Association of mitral annulus calcification, aortic valve sclerosis and aortic root calcification with abnormal myocardial perfusion single photon emission tomography in subjects age < or =65 years old. J Am Coll Cardiol. 2001; 38: 1988-93.
47. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005; 352: 2389-97.
48. Chandra HR, Goldstein JA, O'Neill C, Choudhary N, George PB, Gangasani SR, et al. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol. 2004; 43: 169-75.
49. Tolstrup K, Crawford MH, Roldan CA. Morphologic characteristics of aortic valve sclerosis by transesophageal echocardiography: importance for the prediction of coronary artery disease. Cardiology. 2002; 98: 154-8.